IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of		MAIL STOP
Scarampi Sebastiano et al.		Group Art Unit: 1611
Application No.: 10/751,276)		Examiner: Isis A D Ghali
Filed:	January 2, 2004)	Confirmation No.: 7478
For:	GILSONITE DERIVED PHARMACEUTICAL DELIVERY COMPOSITIONS AND METHODS)	

THIRD INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The information is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Continued examination is requested and the fee required under 37 C.F.R. § 1.17(e) accompanies the present submission.

The Examiner's attention is directed to copending application numbers 10/887,466, naming Sebastiano Scarampi et al. as inventor(s) and filed on July 7, 2004 and 10/751,276, Sebastiano Scarampi et al. as inventor(s) and filed on January 2, 2004. The copending applications and the documents of record in the copending application are listed on the attached form PTO-1449. Since the copending application is available in the Patent Application Information Retrieval (PAIR) system, a copy of the copending application is not required to be submitted. By citation to the copending application, confidentiality is not waived and the Office is requested to maintain the confidentiality of the copending application under 35 U.S.C. § 122.

THIRD Information Disclosure Statement Application No. <u>10/751,276</u> Attorney Docket No. <u>1033292-000004</u> Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

By:

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: June 22, 2009

Brian R. O'Shaughnessy Registration No. 32747

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620